Problem:
Therapeutic antibodies, for example Rituximab which recognises CD20 on B lymphoma cells, can cause adverse effects.
One reason behind these adverse effects could of course be an over-response of immune cells stimulated by the Fc region of antibodies attached to lymphona cells.
However, it could also be thinkable that the immune system launches a response against the antibody itself, recognising it as foreign.
Question: Does this occur? Give its detailed discription.
Question: What part of the injected antibody acts as the epitope recognised by immune cells as foreign?